

Table of Contents

	Page
Preface by the Minister of Public Health	
Issue No. 1 : What is the rationale behind the Government Use of Patents on the three drugs? Is this movement in compliance with the national and international legal framework?	1
Issue No. 2 : Why was there no prior discussion and negotiation with the drug companies?	5
Issue No. 3 : Why has the Ministry of Public Health turned down requests from drug companies to discuss and negotiate even after issuing the Government Use of Patent?	8
Issue No. 4 : What are the mechanisms and criteria used to determine which drugs to issue Government Use of Patent? Will there be additional Government Use for more drugs in the near future? Would these movements eventually lead to the failure of the Intellectual property systems?	11
Issue No. 5 : The Government Use of Patents will save the government some funds but what are the benefits to the people?	13
Issue No. 6 : What will the implications on the Thai export and economy and multinational industries be in Thailand?	16
Issue No. 7 : Has the Ministry of Public Health consulted with other ministries and why not bring it to the decision of the Cabinet?	18
Issue No. 8 : Will the issuing of Government Use result in a step backward for development in Drug Research and Development in Thailand?	20
Issue No. 9 : What are the views of the World Health Organization and other international organizations on this movement?	21
Issue No.10 : How can we be sure that the drugs derived from the Government Use of Patents will be equivalent in quality to the patented products?	22

Document No. 1 : Agreement on Trade Related Aspects of Intellectual Properties Rights (TRIPs) article 31 (b)	23
Document No. 2 : Doha Ministerial Declaration on TRIPs Agreement and Public Health	24
Document No. 3 : Government Use and the Thai Patent Act B.E. 2522 (A.D. 1979) as amended by the Patent Act (No. 3) B.E. 2542 (A.D. 1999)	26
Document No. 4 : Thai Law on Government Use Licenses in Thailand as explained by Sean Flynn, Associate Director of the Program on Information Justice and Intellectual Property, the American University, Washington College of Law	31
Document No. 5 : Department of Disease Control Public Announcement on the Government Use of Patent on Efavirenz	37
Document No. 6 : Department of Disease Control Public Announcement on the Government Use of Patent on Lopinavir+Ritonavir	40
Document No. 7 : Permanent Secretary Office Public Announcement on the Government Use of Patent on Clopidogrel	43
Document No. 8 : Letter from the Department of Disease Control to Merck Sharp and Dohme	45
Document No. 9 : Letter from the Department of Disease Control to Abbott Laboratories Ltd.	47
Document No. 10 : Letter from the Permanent Secretary Office to the Sanofi-Synthelabo (Thailand) Limited	49
Document No. 11 : Letter from 22 US Congressmen to the Honorable Susan C. Schwab, the United States Trade Representative, dated 10 January 2007	51

- Document No. 12 :** Letter from the Honorable Susan C. Schwab, the United States Trade Representative to the Honorable Sander M. Levin, member of congress of the United States of America, dated 17 January 2007 54
- Document No. 13 :** Letter from the Dr. Margaret Chan, the Director General of the World Health Organization to the Honorable Dr. Mongkol Na Songkhla, the Minister of Public Health of Thailand, dated 7 February 2007 55
- Document No. 14 :** Table of the examples of the attempts and the implementation of Compulsory Licensing/Government Use of Patent on certain drugs in some developing and developed countries 57
- Document No. 15 :** Recent examples of the movements on the use of compulsory licenses around the world 60
- Document No. 16 :** Public Health Ministerial Order 360/2548, dated 4 April 2005, appointing the Ad hoc Working Group to negotiate the price of patented essential drugs 67
- Document No. 17 :** Brief report of the output from the Working Group to negotiate the price of patented essential drugs 69
- Document No. 18 :** Letter from the Managing Director of the Merck Sharp and Dohme, Thailand, to the Director General of Department of Disease Control explaining the reason why the company can not reduce the price of Efavirenz, dated 27 January 2005 71
- Document No. 19 :** Ministerial Order establishing the Committee to negotiate the Price of Patented Essential Drugs, signed by the Minister of Public Health, dated 16 February 2007 72
- Document No. 20 :** Letter from the Managing Director of Merck Sharp and Dohme, dated 6 February 2007, to the Director General of the Disease Control Department proposing the latest price of Efavirenz, with 6 conditions 74

	Page
Document No. 21 : Announcement by Merck Sharp and Dohme on global price reduction on Efavirenz, dated 14 February 2007	75
Document No. 22 : National Health Security Board order, dated 17 April 2006, establishing the Subcommittee for Implementing the Government Use of Patent for the Patented Essential Drugs	79
Document No. 23 : Letter of appreciation from the Executive Director of UNAIDS, Dr. Peter Piot, dated 26 December 2006	81
Document No. 24 : Letter of appreciation and support from the Director of Medecins Sans Frontieres, USA, Nicholas de Torrente, and MSF Thailand, Paul Cawthorne, dated 29 December 2006	82
Document No. 25 : Letter of support from the Third World Network, dated 23 February 2007	84
Document No. 26 : Letter of support from Director of the Consumer Project on Technology, James Love, New York, USA, dated 11 December 2006	86
Document No. 27 : Letter of support from the Clinton Foundation, dated 16 February 2007	93

สำหรับเพื่อการศึกษาและ
การวิจัยเท่านั้น

For educational use and reference only